Webinar: Patient Perspectives on Liquid Biopsy in Precision Oncology

Webinar summary

In this webinar, Nikki Martin, Senior Director of Precision Medicine Initiatives at the LUNGevity Foundation, presents patient-centered perspectives on liquid biopsy within the context of precision oncology for lung cancer. The presentation focuses on patient understanding of biomarker testing, access to liquid biopsy technologies, communication challenges, and the role of liquid biopsy in treatment selection and clinical trial access. 

This [story website or documents] may contain general information relating to various medical conditions or their treatment. This information is provided for informational purposes only and is not meant to be a substitute for advice provided by a doctor or other qualified health care professional. Patients should always consult with a doctor or other health care professional for medical advice or information about diagnosis and treatment.

Study overview

The presentation examines how patients experience biomarker testing and liquid biopsy in real-world oncology settings, particularly in lung cancer where precision medicine approaches are more broadly established. Insights were gathered through engagement with patients within the LUNGevity network to better understand awareness, perceived benefits, concerns, and barriers associated with liquid biopsy testing.

Key themes explored include:

• Patient understanding of biomarkers and liquid biopsy terminology
• Barriers to accessing biomarker testing
• Perceived benefits and limitations of liquid biopsy
• Patient concerns regarding treatment decisions and testing accuracy
• Opportunities to improve communication, education, and access

The discussion emphasizes that while liquid biopsy technologies continue to advance, patient education and engagement remain critical components of successful implementation in precision oncology workflows. 

Key findings

Patients seek foundational understanding of biomarker testing

• Patients commonly ask three primary questions: what biomarkers are, why they are important, and whether biomarkers can be inherited
• Most patients require guidance from healthcare providers to understand these concepts and their implications for treatment selection

Patients want active participation in care decisions

• Patients do not want to remain passive participants during diagnosis and treatment planning
• They seek inclusion within the care team and want access to information that supports informed decision-making
• Expectations surrounding treatment and diagnostic workflows are highly important to patients

Significant barriers to biomarker testing persist

• Access barriers are amplified among underserved populations, including patients with lower socioeconomic status, lower health literacy, limited insurance coverage, language barriers, and reduced provider access to precision oncology expertise
• Variability in provider familiarity with guideline-recommended testing also impacts patient access to biomarker testing

Patient understanding of liquid biopsy varies widely

• Some patients interpret “liquid biopsy” literally and lack understanding of its molecular applications
• Other patients possess more advanced knowledge regarding the role of liquid biopsy in treatment selection and monitoring
• Confusion exists between liquid biopsy applications for treatment selection and minimal residual disease (MRD) testing

Patients recognize practical benefits of liquid biopsy

• Patients identified minimally invasive sampling and faster turnaround time as major advantages
• Faster testing was associated with earlier treatment initiation from the patient perspective
• Patients also expressed interest in future liquid biopsy applications for cancer screening

Concerns regarding test reliability and clinical interpretation

• Patients expressed concern that liquid biopsy might fail to detect actionable biomarkers
• Discordance between tissue-based and blood-based test results created uncertainty and anxiety for some patients
• Patients were concerned that incomplete or delayed molecular results could impact treatment selection decisions

Terminology and communication remain major challenges

• Technical and industry-derived terminology contributes to patient confusion
• Improved alignment among laboratories, providers, advocacy organizations, and industry stakeholders was identified as important for standardizing patient-facing communication
• Participants emphasized the value of patient-friendly explanations within laboratory reports and provider discussions

Educational and policy improvements are needed

• Increased education for healthcare providers was identified as a key priority
• Clear reimbursement policies for concurrent tissue and blood-based testing were highlighted as important opportunities
• Improved communication from laboratories, oncologists, nurses, and advocacy organizations was emphasized as essential for patient engagement

This webinar highlights the importance of integrating patient perspectives into the implementation of liquid biopsy technologies in precision oncology. While patients recognize the practical advantages of minimally invasive testing and rapid turnaround times, substantial variability remains in understanding of biomarker testing, liquid biopsy applications, and result interpretation.

The findings emphasize the need for improved education, standardized communication strategies, and expanded access to biomarker testing to support informed patient participation in precision oncology decision-making. 

You may also like

PMR-005525